Related Experiment Videos
[Intravesical BCG therapy for superficial bladder cancer]
Hinyokika Kiyo. Acta Urologica Japonica
|November 7, 1998
Summary
Intravesical bacillus Calmette-Guerin (BCG) therapy after bladder tumor resection is effective for superficial bladder cancer. This treatment shows high success rates, preventing recurrence and disease progression in most patients.
Area of Science:
- Oncology
- Urology
Context:
- Superficial bladder cancer recurrence is common after transurethral resection.
- Intravesical therapies are crucial for managing non-muscle invasive bladder cancer.
Purpose:
- To evaluate the efficacy of intravesical bacillus Calmette-Guerin (BCG) therapy using the Tokyo 172 strain.
- To assess recurrence and progression rates in patients with superficial bladder cancer treated with BCG post-TUR-Bt.
Summary:
- 35 patients with superficial bladder cancer received weekly intravesical BCG instillations for 6 weeks post-TUR-Bt.
- One and two-year non-recurrence rates were 81.7% and 58.4%, respectively.
- Overall, 83% of patients achieved success after one or two cycles of BCG, with a low progression rate of 5%.
Impact:
- Intravesical BCG therapy demonstrates significant potential in preventing superficial bladder cancer recurrence and progression.
- BCG instillation can be effective even for recurrent cases previously treated with other intravesical agents.
- This therapy offers a promising approach to improve long-term outcomes for bladder cancer patients.